Roche Holding AG / Sosei Group Corporation (Sosei Heptares)
2019 · Licensing/Option · $1.0B · Complete
Announcement Sentiment
88
Strongly positive
Sosei Heptares and Genentech (Roche) signed a multi-target research collaboration and license agreement leveraging Sosei's StaR/SBDD GPCR drug-design platform. Sosei received $26M in upfront and near-term payments and is eligible for over $1B in research, development and commercial milestones plus royalties. Genentech receives exclusive global rights.